MarketPeel
Insider Trading Intelligence
EK

Eric Karas

SPRY
CHIEF COMMERCIAL OFFICER · ARS PHARMACEUTICALS, INC. · CIK 0001951287
FILING MIX · LIFETIME45%/55%
BUYS
13
SELLS
16
TOTAL VALUE
$1.45M
COMPANIES
1
ACTIVE SINCE
Nov 2022
HOLDINGS NOW
12,176
AVG SELL PX
$13.74
TRADE KIND
SHOWING 29 / 29
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
7 backtested trades · 8 horizons · 7 pending
Forward-return performance of every backtestable P/S trade by Eric Karas, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d7+57.14%-2.88%+0.69%-3.58%-1.85%
14d7+57.14%-5.72%-0.42%-5.30%-1.55%
30d7+42.86%-0.60%+0.10%-0.70%+7.55%
60d7+85.71%-6.64%+3.75%-10.38%-7.01%
90d7+85.71%-19.93%+4.22%-24.15%-22.37%
180d7+71.43%-17.20%+7.16%-24.36%-25.24%
1y7+100.00%-32.47%+17.35%-49.81%-48.41%
2y7(7 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
SPRY · 12,176 shares · as of Jun 12, 2026
0153,647307,294460,941614,5882023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 13 buys / 16 sellsCOVERAGE · 15 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
25,000$10.00$250.0K12,176Jun 12, 2026Jun 12, 2026View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASE
Chief Commercial Officer
25,000$1.50$37.5K37,176Jun 12, 2026Jun 12, 2026View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE
Chief Commercial Officer
25,000519,588Jun 12, 2026Jun 12, 2026View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
240,000240,000Jan 2, 2026Jan 5, 2026View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASE
Chief Commercial Officer
15,000$1.50$22.5K25,315Jul 1, 2025Jul 3, 2025View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
15,000$16.99$254.9K10,315Jul 1, 2025Jul 3, 2025View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE
Chief Commercial Officer
15,000544,588Jul 1, 2025Jul 3, 2025View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE
Chief Commercial Officer
15,000559,588Jun 18, 2025Jun 20, 2025View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASE
Chief Commercial Officer
15,000$1.50$22.5K22,696Jun 18, 2025Jun 20, 2025View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
15,000$16.00$240.0K7,696Jun 18, 2025Jun 20, 2025View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASE
Chief Commercial Officer
10,000$1.50$15.0K17,696Mar 20, 2025Mar 21, 2025View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE
Chief Commercial Officer
10,000574,588Mar 20, 2025Mar 21, 2025View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
10,000$14.00$140.0K7,696Mar 20, 2025Mar 21, 2025View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
152,300152,300Jan 2, 2025Jan 3, 2025View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASE
Chief Commercial Officer
6,283$1.50$9.4K11,976Dec 4, 2024Dec 4, 2024View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE
Chief Commercial Officer
6,283584,588Dec 4, 2024Dec 4, 2024View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
6,283$14.00$88.0K5,693Dec 4, 2024Dec 4, 2024View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE
Chief Commercial Officer
3,717590,871Dec 2, 2024Dec 4, 2024View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
3,717$14.11$52.5K5,693Dec 2, 2024Dec 4, 2024View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASE
Chief Commercial Officer
3,717$1.50$5.6K9,410Dec 2, 2024Dec 4, 2024View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASE
Chief Commercial Officer
10,000$1.50$15.0K15,693Sep 18, 2024Sep 19, 2024View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
10,000$14.00$140.0K5,693Sep 18, 2024Sep 19, 2024View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE
Chief Commercial Officer
10,000594,588Sep 18, 2024Sep 19, 2024View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
10,000$14.00$140.0K5,693Aug 19, 2024Aug 21, 2024View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE
Chief Commercial Officer
10,000604,588Aug 19, 2024Aug 21, 2024View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASE
Chief Commercial Officer
10,000$1.50$15.0K15,693Aug 19, 2024Aug 21, 2024View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
200,000200,000Jan 2, 2024Jan 4, 2024View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
50,00050,000Jan 3, 2023Jan 5, 2023View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
614,588614,588Nov 8, 2022Nov 10, 2022View →
Other insiders · SPRY
Loading peer insiders…
About this filer
CIK 0001951287
ROLE
Chief Commercial Officer
PRIMARY
SPRY
COMPANIES
1
ACTIVE SINCE
Nov 2022
MARKETPEEL · /INSIDER/0001951287DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback